This study elucidates PSC activation as the central mechanism underlying the pro-tumoral effects of CTHRC1 and suggests that future studies on CTHRC1 as a potential therapeutic target for pancreatic cancer are warranted. This evidence concerns the gene CTHRC1 and familial pancreatic carcinoma.